אינג'י 10 מג20 מג טבליות

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

EZETIMIBE; SIMVASTATIN

Verfügbar ab:

MERCK SHARP & DOHME ISRAEL LTD

ATC-Code:

C10AA01

Darreichungsform:

טבליה

Zusammensetzung:

EZETIMIBE 10 MG; SIMVASTATIN 20 MG

Verabreichungsweg:

פומי

Verschreibungstyp:

מרשם נדרש

Hergestellt von:

MERCK SHARP & DOHME (ITALIA) S.P.A.

Therapiegruppe:

SIMVASTATIN

Therapiebereich:

SIMVASTATIN

Anwendungsgebiete:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Berechtigungsdatum:

2012-04-30